Overactive Bladder Treatment Market to Hit USD 4.89 Billion by 2030 driven by the Growing Awareness about OAB and Availability of Advanced Diagnostic Tools | Research by SNS Insider

The development of novel therapies with improved efficacy and safety profiles is expected to further boost the growth of the overactive bladder treatment market in the coming years.

1401 Lavaca ST 800, Austin Tx 78701


Pune, April 04, 2023 (GLOBE NEWSWIRE) -- As per the report from SNS Insider, the Overactive Bladder Treatment Market was assessed at USD 3.63 billion in 2022 and is projected to expand to USD 4.89 billion by 2030, registering a compound annual growth rate (CAGR) of 3.8% during the forecast period of 2023-2030.

Market Overview

Overactive Bladder (OAB) is a common medical condition characterized by a sudden and uncontrollable urge to urinate, which may lead to involuntary leakage of urine, also known as urinary incontinence. Overactive bladder can be caused by several factors such as nerve damage, bladder infections, or hormonal changes, but it is most commonly associated with aging. The treatment of overactive bladder involves a combination of lifestyle modifications, medications, and, in some cases, surgical procedures.

Market Analysis

The drivers for the Overactive bladder treatment market include factors such as the increasing prevalence of overactive bladder (OAB) among aging populations, rising awareness about OAB and its treatment options, the growing availability of effective OAB treatments, and the emergence of novel therapies with improved efficacy and safety profiles. Additionally, the expanding healthcare infrastructure in developing regions, increasing healthcare expenditure, and the growing adoption of minimally invasive surgical procedures are also expected to drive the growth of the market in the coming years.

Get a Sample Report of Overactive Bladder Treatment Market@  https://www.snsinsider.com/sample-request/2586

Key Company Profile Listed in this Report Are:

  • Astellas Pharma, Inc.
  • Mylan N.V.
  • Endo International PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • Teva Pharmaceutical Industries Limited
  • Allergan, Plc
  • Sanofi
  • Aurobindo Pharma Limited,
  • Pfizer, Inc.
  • Medtronic plc.

Impact of Recession on Overactive Bladder Treatment Market

The impact of a recession on the overactive bladder treatment market is complex and can be influenced by several factors. While economic downturns can lead to reduced healthcare spending and limited access to healthcare services, the growing prevalence of OAB among aging populations may counterbalance this impact by driving demand for effective treatment options.

Key Regional Developments

As per the market analysis, North America holds the largest share of the global overactive bladder treatment market, owing to factors such as high awareness levels, well-established healthcare infrastructure, and a significant number of patients suffering from overactive bladder in the region. Moreover, the North American market is characterized by the presence of major market players, a higher proportion of the elderly population, and an increase in lifestyle diseases such as diabetes, which can lead to overactive bladder. Europe, on the other hand, is the second-largest market for overactive bladder treatment, primarily driven by increasing healthcare expenditure, rising geriatric population, and a growing number of patients suffering from overactive bladder.

Overactive Bladder Treatment Market Report Scope:

Report Attributes  Details
Market Size in 2022  US$ 3.63 Billion
Market Size by 2030  US$ 4.89 Billion
CAGR  CAGR of 3.8% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Overactive Bladder Treatment Market: Key Segmentation • By Disease Type (Idopathic OAB and Neurogenic OAB)
• By Drug type (Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron)
• By Pharmacotherapy (Fesoterodine, Tolterodine, Trospium, Anticholinergics, Solifenacin, Oxybutynin, Darifenacin)
Key Regional Coverage North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)

Do you have any specific queries related to this research? Ask Your Query@ https://www.snsinsider.com/enquiry/2586

Key Takeaway from Overactive Bladder Treatment Market Study

  • The mirabegron segment is expected to continue to experience substantial growth over the next few years due to its high efficacy and safety profile, as well as its increased adoption by healthcare professionals.
  • The fesoterodine segment is projected to hold a significant share in the market. This can be attributed to the medication's high efficacy in treating OAB symptoms and its increased adoption by healthcare professionals.

Recent Developments Related to the Overactive Bladder Treatment Market

  • Alembic Pharmaceuticals, a leading Indian pharmaceutical company, has received the approval of the United States Food and Drug Administration (USFDA) for its overactive bladder treatment drug. The drug, which is expected to hit the US market soon, is designed to provide relief to people suffering from symptoms such as frequent urination, urgency to urinate, and incontinence.
  • Indian pharmaceutical company MSN Group has announced the launch of its new drug Fesobig, which is designed to treat urinary incontinence and overactive bladder. The drug, which has received approval from the Drugs Controller General of India, is expected to offer an effective and convenient treatment option for patients suffering from these conditions.

Table of Contents

1. Introduction

2. Research Methodology

3. Market Dynamics

4. Impact Analysis

5. Value Chain Analysis

6. Porter’s 5 Forces Model

7. PEST Analysis

8. Overactive Bladder Treatment Market, By Type

9. Overactive Bladder Treatment Market, By Disease Type

10. Overactive Bladder Treatment Market, By Pharmacotherapy

11. Regional Analysis

12. Company Profiles

13. Competitive Landscape

14. Conclusion

Buy Single-User PDF of Overactive Bladder Treatment Market Report@ https://www.snsinsider.com/checkout/2586

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominate the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Access Complete Report Details@ https://www.snsinsider.com/reports/overactive-bladder-treatment-market-2586

 

Contact Data